PE20231731A1 - Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1 - Google Patents
Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1Info
- Publication number
- PE20231731A1 PE20231731A1 PE2023002182A PE2023002182A PE20231731A1 PE 20231731 A1 PE20231731 A1 PE 20231731A1 PE 2023002182 A PE2023002182 A PE 2023002182A PE 2023002182 A PE2023002182 A PE 2023002182A PE 20231731 A1 PE20231731 A1 PE 20231731A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- methods
- administration
- materials
- monitoring cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000012544 monitoring process Methods 0.000 title abstract 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 abstract 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN ANTICUERPO ANTI-MCL-1 O UN FRAGMENTO DE UNION A ANTIGENO DEL MISMO QUE COMPRENDE UNA LCDR1 DE SEQ ID NO: 4, UNA LCDR2 DE SEQ ID NO: 5, UNA LCDR3 DE SEQ ID NO: 6, UNA HCDR1 DE SEQ ID NO: 16, UNA HCDR2 DE SEQ ID NO: 17, Y UNA HCDR3 DE SEQ ID NO: 18; O QUE COMPRENDA UNA LCDR1 DE SEQ ID NO: 10, UNA LCDR2 DE SEQ ID NO: 11, UNA LCDR3 DE SEQ ID NO: 12, UNA HCDR1 DE SEQ ID NO: 22, UNA HCDR2 DE SEQ ID NO: 23 Y UNA HCDR3 DE SEQ ID NO: 24. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE SIENDO UTIL EN METODOS DE SEGUIMIENTO DE CELULAS CANCEROSAS QUE EXPRESAN MCL-1 Y METODOS DE TRATAMIENTO DE CANCERES SANGUINEOS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143682P | 2021-01-29 | 2021-01-29 | |
| PCT/US2022/014401 WO2022165240A1 (en) | 2021-01-29 | 2022-01-28 | Materials and methods for monitoring cancer by administering an anti-mcl1 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231731A1 true PE20231731A1 (es) | 2023-10-26 |
Family
ID=82654972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002182A PE20231731A1 (es) | 2021-01-29 | 2022-01-28 | Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240117069A1 (es) |
| EP (1) | EP4284826A1 (es) |
| JP (1) | JP2024508222A (es) |
| KR (1) | KR20230135087A (es) |
| CN (1) | CN116806156A (es) |
| AU (1) | AU2022214936A1 (es) |
| CA (1) | CA3203780A1 (es) |
| CL (1) | CL2023002189A1 (es) |
| CO (1) | CO2023009810A2 (es) |
| CR (1) | CR20230388A (es) |
| IL (1) | IL303844A (es) |
| MX (1) | MX2023008971A (es) |
| PE (1) | PE20231731A1 (es) |
| WO (1) | WO2022165240A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020086321A1 (en) * | 1993-02-02 | 2002-07-04 | Craig Ruth W. | Myeloid cell leukemia associated gene MCL-1 |
| US20100040606A1 (en) * | 2006-03-06 | 2010-02-18 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
| NZ597767A (en) * | 2007-05-21 | 2013-06-28 | Bristol Myers Squibb Co | Antibodies to IL-6 and use thereof |
| BR112016015589A2 (pt) * | 2014-01-06 | 2017-10-31 | Hoffmann La Roche | módulos de trânsito monovalentes para a barreira hematoencefálica |
| US20200399373A1 (en) * | 2018-02-14 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule and combination |
| JP7205691B2 (ja) * | 2019-01-23 | 2023-01-17 | ウシオ電機株式会社 | 抗イヌプロカルシトニン抗体及びこれを用いた検査用キット |
-
2022
- 2022-01-28 AU AU2022214936A patent/AU2022214936A1/en active Pending
- 2022-01-28 MX MX2023008971A patent/MX2023008971A/es unknown
- 2022-01-28 IL IL303844A patent/IL303844A/en unknown
- 2022-01-28 WO PCT/US2022/014401 patent/WO2022165240A1/en active Application Filing
- 2022-01-28 PE PE2023002182A patent/PE20231731A1/es unknown
- 2022-01-28 EP EP22746737.0A patent/EP4284826A1/en active Pending
- 2022-01-28 KR KR1020237026043A patent/KR20230135087A/ko unknown
- 2022-01-28 CR CR20230388A patent/CR20230388A/es unknown
- 2022-01-28 US US18/275,169 patent/US20240117069A1/en active Pending
- 2022-01-28 JP JP2023543373A patent/JP2024508222A/ja active Pending
- 2022-01-28 CA CA3203780A patent/CA3203780A1/en active Pending
- 2022-01-28 CN CN202280008569.5A patent/CN116806156A/zh active Pending
-
2023
- 2023-07-25 CL CL2023002189A patent/CL2023002189A1/es unknown
- 2023-07-25 CO CONC2023/0009810A patent/CO2023009810A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022214936A1 (en) | 2023-06-29 |
| CR20230388A (es) | 2023-10-05 |
| CO2023009810A2 (es) | 2023-08-09 |
| KR20230135087A (ko) | 2023-09-22 |
| JP2024508222A (ja) | 2024-02-26 |
| IL303844A (en) | 2023-08-01 |
| WO2022165240A1 (en) | 2022-08-04 |
| CA3203780A1 (en) | 2022-08-04 |
| US20240117069A1 (en) | 2024-04-11 |
| CL2023002189A1 (es) | 2024-03-01 |
| AU2022214936A9 (en) | 2023-08-17 |
| CN116806156A (zh) | 2023-09-26 |
| MX2023008971A (es) | 2023-08-15 |
| EP4284826A1 (en) | 2023-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20220218A1 (es) | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20231049A1 (es) | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20081503A1 (es) | Miembros de union para il-6 | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| NZ740221A (en) | St2l antagonists and methods of use | |
| PE20120014A1 (es) | Anticuerpos humanos de alta afinidad contra pcsk9 |